Charles River Laboratories International Return on Equity

Charles River Laboratories International (CRL) currently reports a ROE of 1.25%. That is below the Healthcare sector average of 13.26%. Use the charts on this page to explore Charles River Laboratories International's ROE history and peer comparisons.

Charles River Laboratories International's ROE of 1.25% is lower than the Healthcare sector average of 13.26%. That is roughly 90.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Charles River Laboratories International's current 1.25% should be judged against Healthcare norms (sector average: 13.26%) and against CRL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 1.25%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.26%. From there, open related valuation or income-statement pages for Charles River Laboratories International, and consider following CRL for alerts when major investors trade the stock.

Charles River Laboratories International is classified in the Healthcare sector. On ROE, it currently shows 1.25% versus a sector average near 13.26%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CRL with unrelated industries.